Search

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)

Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4. 

Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics

Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.

The collaboration on social science and immunisation (COSSI): Global lessons from a successful Australian research and practice network

Samantha Carlson BSc MPH PhD Senior Research Officer Samantha.carlson@thekids.org.au Senior Research Officer @samicarlson ORCID Dr Carlson is an

Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccination

Early 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG

Development of a human papillomavirus vaccination intervention for Australian adolescents

Intervention to address young people's low levels of understanding, to promote their involvement in consent and reduce vaccination-related fear and anxiety.

Transiently increased IgE responses in infants and pre-schoolers receiving only (DTaP) vaccines compared to those initially receiving at least one dose of DTwP vaccine

Confirm the generalised IgE-trophic activity of the DTaP vaccine in pre-schoolers and demonstrate similar (albeit transient) effects in infants

Establishing a process for conducting cross-jurisdictional record linkage in Australia

We outline the processes involved in conducting a Proof of Concept data linkage project including the implementation of national data integration principles

Continuous active surveillance of adverse events following immunisation using SMS technology

Automated SMS-based reporting can facilitate sustainable, real-time, monitoring of adverse reactions and early identification of potential vaccine safety issues

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal

The impact of the 23vPPV booster on IPD incidence among Australian Indigenous children is unclear from regional reports of small case numbers.

PneuMum: Impact from a trial of maternal pneumococcal vaccination on middle ear disease amongst Indigenous infants

This study was unable to demonstrate efficacy of 23vPPV in pregnancy against the co-primary outcomes of either all-cause infant ear disease.